Given the stale $600M valuation from 2022, the company's recent pivot and downsizing, and critical competitive threats, the expected equity upside over a 2-year horizon is deeply negative at -92%.Read more

Negative expected return of -71% over 2 years due to an overstated entry valuation ($5.2B at 26x trailing revenue), growth deceleration, likely dilution from a future raise, and high incumbent threat.Read more